Analysis of genotyping and 6 nucleosides' resistance of HBV in patients with chronic hepatitis B

doi:10.3969/j.issn.1673-8640.2019.11.008

Abstract

Abstract:

Objective To investigate the distribution characteristics of hepatitis B virus（HBV） genotypes,the variation of drug resistance genes and the drug resistance of 6 nucleosides in patients with chronic hepatitis B（CHB）. Methods The HBV DNA of 82 CHB patients was determined by real-time fluorescence quantitative polymerase chain reaction（PCR）. The detection of HBV drug resistance gene was carried out by nested PCR to amplify the gene fragment of HBV P region. The Sanger sequencing method was used to detect the gene drug resistance site of HBV P region. Alanine aminotransferase（ALT）,aspartate aminotransferase（AST）,hepatitis B e antigen（HBeAg） and hepatitis B e antibody（HBeAb） were determined. Results Totally,25 cases（30.5%） of HBV type B,51 cases（62.2%） of HBV type C,5 cases（6.1%） of HBV B+C mixed type and 1 case（1.2%） of other type were detected in 82 CHB patients. There was no statistical significance in ALT,AST,HBV DNA load,HBeAg and HBeAb between type B and type C CHB patients（P>0.05）. The sensitivities of adefovir dipivoxil and tenofovir dipivoxil were 64.63%,and the decreased sensitivity of entecavir accounted for 34.15%. The resistance rate of telbivudine was 53.66%,those of emtricitabine and lamivudine were 50.0%. Conclusions The main HBV genotypes of 82 patients with CHB are type C and type B. Adefovir dipivoxil and tenofovir dipivoxil have high sensitivities.

Key words: Hepatitis B virus, Genotype, Gene mutation, Drug resistance, Chronic hepatitis B

CLC Number:

R446.1

GAO Wanqin, ZHANG Qin, ZHU Lin, WU Bin, HE Wentao, ZHANG Tinglu, ZHAO Changxin. Analysis of genotyping and 6 nucleosides' resistance of HBV in patients with chronic hepatitis B[J]. Laboratory Medicine, 2019, 34(11): 994-997.

Figures/Tables 2

References 11

[1]	World Health Organization. Hepatitis B[EB/OL]. (2012-08-28)[2018-07-18]. .
[2]	TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
[3]	何成山. 乙型肝炎病毒Pre-S/S区基因突变对乙型肝炎病毒表面抗原检测的影响[J]. 检验医学,2018,33(10):949-953.
[4]	中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志,2015,31(12):1941-1960.
[5]	任速飞,王华钧. 核苷类药物相关乙型肝炎病毒P基因区耐药变异测序分析[J]. 上海预防医学,2015,27(4):196-197.
[6]	马金春,王鲁文,廖永锋,等. 黄石地区慢性无症状乙型肝炎病毒携带者的基因型分布[J]. 中西医结合肝病杂志,2006,16(5):287-289.
[7]	中华人民共和国卫生部. 2006—2010年全国乙型病毒性肝炎防治规划[J]. 中华人民共和国卫生部公报,2006,3:11-14
[8]	张廷禄,梁晓雷,营亮,等. 1997—2008年连云港市乙型肝炎发病趋势分析[J]. 预防医学情报杂志,2010,26(7):507-510.
[9]	文娟. HBV变异、宿主HLA基因多态性及其交互作用与肝细胞癌发病风险的关联研究[D]. 南京:南京医科大学,2015.
[10]	PARK Y M.Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus geome[J]. World J Hepatol,2015,7(1):113-120.
[11]	林菲,姚贝,胥婕,等. 153例慢性HBV感染者核苷和核苷酸类药物的耐药变异位点分析[J]. 临床肝胆病杂志,2014,30(3):269-273.

基因型	例数	年龄（岁）	HBV DNA （×10³ IU/mL）	ALT （U/L）	AST （U/L）	HBeAg阳性 [例（%）]	HBeAb阳性 [例（%）]
B型	25	34.2±13.1	5.4±1.4	124±57	101±45	18（72.0）	7（28.0）
C型	51	36.1±14.3	6.2±1.6	159±63	115±51	38（74.5）	13（25.5）
B+C混合型	5	31.5±7.6	5.7±1.3	137±52	96±35	4（80.0）	1（20.0）

基因型	例数	年龄（岁）	HBV DNA （×10³ IU/mL）	ALT （U/L）	AST （U/L）	HBeAg阳性 [例（%）]	HBeAb阳性 [例（%）]
B型	25	34.2±13.1	5.4±1.4	124±57	101±45	18（72.0）	7（28.0）
C型	51	36.1±14.3	6.2±1.6	159±63	115±51	38（74.5）	13（25.5）
B+C混合型	5	31.5±7.6	5.7±1.3	137±52	96±35	4（80.0）	1（20.0）

药物名称	例数	敏感	敏感性下降	耐药
恩曲他滨	82	20（24.39）	3（3.66）	41（50.00）
恩替卡韦	82	20（24.39）	28（34.15）	9（10.98）
拉米夫定	82	20（24.39）	3（3.66）	41（50.00）
替诺福韦酯	82	53（64.63）	10（12.20）	0（0）
阿德福韦酯	82	53（64.63）	0（0）	11（13.42）
替比夫定	82	20（24.39）	0（0）	44（53.66）

药物名称	例数	敏感	敏感性下降	耐药
恩曲他滨	82	20（24.39）	3（3.66）	41（50.00）
恩替卡韦	82	20（24.39）	28（34.15）	9（10.98）
拉米夫定	82	20（24.39）	3（3.66）	41（50.00）
替诺福韦酯	82	53（64.63）	10（12.20）	0（0）
阿德福韦酯	82	53（64.63）	0（0）	11（13.42）
替比夫定	82	20（24.39）	0（0）	44（53.66）

[1]	WANG Chao, ZHAO Yu. Research progress on formation mechanism and eradication strategy of bacterial persisters [J]. Laboratory Medicine, 2023, 38(8): 790-795.
[2]	ZHANG Ying, JING Lijuan, LI Li. Relationship between the expression of miR-138 in peripheral blood mononuclear cells of hepatitis B virus proliferation in carriers [J]. Laboratory Medicine, 2023, 38(6): 559-562.
[3]	ZHU Yurong, ZHANG Dan, HE Yaxing, LI Jingjing, HUANG Jing, LI Ting, LIU Peng, LIU Ronghua. Classification and epidemiology characteristics of Klebsiella pneumoniae isolated from clinic [J]. Laboratory Medicine, 2023, 38(5): 435-440.
[4]	FANG Yongmei, ZHANG Yan, XU Xueying, ZHONG Feng. Correlation of Staphylococcus aureus drug resistance with drug resistance genes and virulence genes [J]. Laboratory Medicine, 2023, 38(4): 357-361.
[5]	WANG Jiawei, ZHU Weinan, CHEN Yingying, JI Ping, WANG Ying. Clinical characteristics，molecular typing and drug resistance genes of carbapenem-resistant Klebsiella pneumoniae isolated from blood culturing [J]. Laboratory Medicine, 2023, 38(4): 362-367.
[6]	REN Yanfei, ZHANG Min, YANG Tao, LI Rongkai, LIANG Xin. Analysis of pathogenic epidemiology of patients with lower respiratory tract infection in respiratory intensive care unit [J]. Laboratory Medicine, 2023, 38(2): 157-162.
[7]	DENG Chen, DAI Jiaze, QIU Lihong, SHEN Weiting, CAI Mufa, LUO Wenying. Molecular epidemic characteristics of hypervirulent Klebsiella pneumoniae in Zhanjiang [J]. Laboratory Medicine, 2023, 38(11): 1026-1031.
[8]	RU Haohao, CHEN Lianyong, YANG Xing, CHEN Tao, YAN Shuangqun, XU Lin. Analysis of rifampicin resistance in Mycobacterium tuberculosis determined by Xpert MTB/RIF and phenotypic drug susceptibility test [J]. Laboratory Medicine, 2023, 38(11): 1032-1035.
[9]	WANG Su, DING Li, JIANG Wenrong, MIAO Yingxin, ZHANG Yanmei, ZHAO Hu. Research progress on drug resistance and treatment strategies of hypervirulent Klebsiella pneumoniae [J]. Laboratory Medicine, 2023, 38(1): 81-86.
[10]	HAO Jiahui, YANG Zehua. Research progress of bacterial integron determination methods [J]. Laboratory Medicine, 2022, 37(9): 887-891.
[11]	LIU Yang, GENG Kunjing, LI Hongjiang, SHI Haoxi, CHEN Sisi. Relationship of 25（OH）D₃ and liver inflammatory stage with the efficacy of antiviral therapy [J]. Laboratory Medicine, 2022, 37(7): 628-631.
[12]	LI Hua, WANG Weiliang, XIE Bei, YANG Yu, MENG Fanrong, WANG Nan, LIU Zhihui, ZHANG Yanbin. Feasibility of the determination of heterogeneous drug resistance to rifampicin in Mycobacterium tuberculosis by flow cytometry [J]. Laboratory Medicine, 2022, 37(6): 577-582.
[13]	SUN Xiaodan, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Research progress on the role of estrogen receptor in osteosarcoma [J]. Laboratory Medicine, 2022, 37(4): 313-318.
[14]	WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359.
[15]	CHEN Yuemei, JIN Yongmei, ZENG Tingting, JIANG Nenggang, LIAO Hongyan. Diagnosis and clinical characteristics of acute myeloid leukemia with BCR-ABL1 accompanied by FLT3-ITD and multiple gene mutations [J]. Laboratory Medicine, 2022, 37(4): 365-369.